LSE:CMCX 2 February 2026

July 3, 2026, 6:45 PM EDT. Patient monitoring names put up mixed Q1s, with revenue beating the Street by 2.3% and stocks adding 3.5% on average after results. DexCom (NASDAQ:DXCM) booked $1.19 billion in Q1 sales, up 15% from a year earlier and 1.4% above estimates, but its full-year outlook landed at the low end for the group, keeping some investors cautious. The sector is helped by more chronic disease and digital health adoption, though it's still dealing with big R&D spend, regulatory hurdles, and price pressure. New AI and machine learning products could push growth. Insulet (NASDAQ:PODD) outperformed this quarter, drawing notice for its tubeless insulin device.